Samide A, Tutunaru B, Varut R, Oprea B, Iordache S
Pharmaceuticals (Basel). 2021; 14(7).
PMID: 34199041
PMC: 8308819.
DOI: 10.3390/ph14070619.
Ensergueix G, Pallet N, Joly D, Levi C, Chauvet S, Trivin C
Clin Kidney J. 2020; 13(4):660-665.
PMID: 32897279
PMC: 7467602.
DOI: 10.1093/ckj/sfz183.
Lehmann D, Williams W
Toxicol In Vitro. 2018; 53:20-28.
PMID: 30048737
PMC: 6763276.
DOI: 10.1016/j.tiv.2018.06.025.
Diehl R, Ferrara F, Muller C, Dreyer A, McLeod D, Fricke S
Cell Mol Immunol. 2016; 14(2):146-179.
PMID: 27721455
PMC: 5301156.
DOI: 10.1038/cmi.2016.39.
Li F, Patterson A, Hofer C, Krausz K, Gonzalez F, Idle J
Biochem Pharmacol. 2010; 80(7):1063-74.
PMID: 20541539
PMC: 2941803.
DOI: 10.1016/j.bcp.2010.06.002.
The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.
Bacolod M, Lin S, Johnson S, Bullock N, Colvin M, Bigner D
Curr Cancer Drug Targets. 2008; 8(3):172-9.
PMID: 18473730
PMC: 3633091.
DOI: 10.2174/156800908784293631.
Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy.
Bodo E, Tobin D, Kamenisch Y, Biro T, Berneburg M, Funk W
Am J Pathol. 2007; 171(4):1153-67.
PMID: 17823286
PMC: 1988866.
DOI: 10.2353/ajpath.2007.061164.
A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo.
Ammons W, Wang J, Yang Z, Tidmarsh G, Hoffman R
Neoplasia. 2007; 9(8):625-33.
PMID: 17786181
PMC: 1950432.
DOI: 10.1593/neo.07343.
Chemical-biological reactions common to teratogenesis and mutagenesis.
Harbison R
Environ Health Perspect. 1978; 24:87-100.
PMID: 17539160
PMC: 1637217.
DOI: 10.1289/ehp.782487.
Clinical pharmacokinetics of cyclophosphamide.
de Jonge M, Huitema A, Rodenhuis S, Beijnen J
Clin Pharmacokinet. 2005; 44(11):1135-64.
PMID: 16231966
DOI: 10.2165/00003088-200544110-00003.
Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study.
Wu J, Reynolds C
J Comput Aided Mol Des. 2000; 14(4):307-16.
PMID: 10815768
DOI: 10.1023/a:1008128023564.
A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
Hassan M, Svensson U, Ljungman P, Bjorkstrand B, Olsson H, Bielenstein M
Br J Clin Pharmacol. 1999; 48(5):669-77.
PMID: 10594468
PMC: 2014348.
DOI: 10.1046/j.1365-2125.1999.00090.x.
Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Granvil C, Ducharme J, Leyland-Jones B, Trudeau M, Wainer I
Cancer Chemother Pharmacol. 1996; 37(5):451-6.
PMID: 8599868
DOI: 10.1007/s002800050411.
Preclinical pharmacokinetics and stability of isophosphoramide mustard.
Zheng J, Chan K, Muggia F
Cancer Chemother Pharmacol. 1994; 33(5):391-8.
PMID: 8306413
DOI: 10.1007/BF00686268.
Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J, Kupker F, Blaschke G, Jurgens H
Cancer Chemother Pharmacol. 1993; 33(1):71-6.
PMID: 8269592
DOI: 10.1007/BF00686026.
Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Kurowski V, Wagner T
Cancer Chemother Pharmacol. 1993; 33(1):36-42.
PMID: 8269587
DOI: 10.1007/BF00686020.
Metabolism of ifosfamide during a 3 day infusion.
Hartley J, Hansen L, Harland S, Nicholson P, Pasini F, Souhami R
Br J Cancer. 1994; 69(5):931-6.
PMID: 8180026
PMC: 1968912.
DOI: 10.1038/bjc.1994.180.
Ifosfamide clinical pharmacokinetics.
Wagner T
Clin Pharmacokinet. 1994; 26(6):439-56.
PMID: 8070218
DOI: 10.2165/00003088-199426060-00003.
Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
Rossi R, Kist C, Wurster U, Kulpmann W, Ehrich J
Pediatr Nephrol. 1994; 8(2):151-6.
PMID: 8018491
DOI: 10.1007/BF00865464.
The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.
Juma F, Rogers H, Trounce J
Br J Clin Pharmacol. 1980; 10(4):327-35.
PMID: 7448105
PMC: 1430090.
DOI: 10.1111/j.1365-2125.1980.tb01768.x.
